Foundation Medicine→Roche
Acquisition · Cash · ROG · announced Jun 19, 2018
Announced
Jun 19, 2018
Closed
Jul 18, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · rounding grid ±$100M · Roche 8-K filing, SEC EDGAR — Foundation Medicine acquisition
$137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
Target
Foundation Medicine
Precision Medicine · Diagnostic / genomic
HQ Cambridge, MA · Founded 2010
Last known · Total company value ~$5.3B fully diluted; Roche paid ~$2.4B for remaining shares (Roche press release, Jun 2018)
Comprehensive genomic profiling (CGP) for cancer — FoundationOne tests guide precision treatment including breast and ovarian cancer
- Roche media release (Jun 19, 2018)
- Fierce Biotech - deal coverage
- SEC EDGAR - 10-K filing (CIK 0001573773, ticker FMI)
Acquirer
Roche (ROG)
Precision Medicine
HQ Basel, Switzerland
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Comprehensive genomic profiling (CGP) — FoundationOne tests identify actionable mutations in breast, ovarian, and other cancers to guide precision treatment selection
Evidence ladder
Tertiary (trade / analyst)
Roche media release (Jun 19, 2018)
Secondary (press / IR)
Fierce Biotech
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- $137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
- Pre-deal valuation sourced from: Roche 8-K filing, SEC EDGAR — Foundation Medicine acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Precision Medicine
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Genomic Health | Exact Sciences | Jul 29, 2019 | same evidence class | |
| GRAIL | Illumina | Sep 21, 2020 | same evidence class | |
| Flatiron Health | Roche | Jan 8, 2018 | same acquirer |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Varian Medical Systems | Siemens Healthineers | Aug 2, 2020 |
Patient empowerment context
Empowerment context — Foundation Medicine
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should) (Company / product site)37%cited HLTH 2022Mapping source →
- Presented with clinical trial as treatment option (Company / product site)1 in 5cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Company / product site)54%cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Flatiron Health
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.